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Objective: To investigate the effects of an ethanol extract of Kalopanax septemlobus
(Thunb.) Koidz. leaf (EEKS) on cell proliferation in human hepatocellular carcinoma
cells and its mechanisms of action.
Methods: Cells were treated with EEKS and subsequently analyzed for cell proliferation
and ﬂow cytometry analysis. Expressions of cell cycle regulators were determined by
reverse transcriptase polymerase chain reaction analysis and Western blotting, and acti-
vation of cyclin-associated kinases studied using kinase assays.
Results: The EEKS suppressed cell proliferation in both HepG2 and Hep3B cells, but
showed a more sensitive anti-proliferative activity in HepG2 cells. Flow cytometry
analysis revealed an association between the growth inhibitory effect of EEKS and with
G1 phase cell cycle arrest in HepG2 cells, along with the dephosphorylation of retino-
blastoma protein (pRB) and enhanced binding of pRB with the E2F transcription factor
family proteins. Treatment with EEKS also increased the expression of cyclin-dependent
kinase (CDK) inhibitors, such as p21WAF1/CIP1 and p27KIP1, without any noticeable
changes in G1 cyclins and CDKs (except for a slight decrease in CDK4). Treatment of
HepG2 cells with EEKS also increased the binding of p21 and p27 with CDK4 and
CDK6, which was paralleled by a marked decrease in the cyclin D- and cyclin E-asso-
ciated kinase activities.
Conclusions: Overall, our ﬁndings suggest that EEKS may be an effective treatment for
liver cancer through suppression of cancer cell proliferation via G1 cell cycle arrest.
Further studies are required to identify the active compounds in EEKS.1. Introduction
Hepatocellular carcinoma (HCC) is currently ranked third
among the most common causes of cancer deaths, and is
particularly prevalent in Asia [1,2]. One well-established factor
for liver cancer is persistent hepatitis B virus infection, but the
causes of HCC involve a complex interaction between numerous
factors [3]. Natural or acquired resistance imposes further limits
on the efﬁcacy of currently available treatments, resulting in
continued poor outcomes inpatients with advanced HCC,
despite recent advances in cancer treatments [4,5]. Newrticle under the CC BY-NC-ND license (http://
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against HCC, are therefore needed.
The current consensus is that the loss of normal cell cycle
control plays an important role in the genesis of most cancers. Cell
cycle progression is a highly ordered and tightly regulated process
that involves multiple checkpoints [6,7]. In eukaryotic cells, each
phase of the cell division cycle is controlled by several protein
kinases, the cyclin-dependent kinases (CDKs), which act in
conjunction with their corresponding regulatory cyclins and CDK
inhibitors. CDK inhibitors, which bind to cyclin-CDK complexes
and render these complexes inactive, are grouped into two distinct
families, the INK4 and CIP/KIP families, based on sequence ho-
mology and targets of inhibition [8]. The INK4 family, including
p15INK4B, p16INK4A, p18INK4C, and p19INK4Dd, interact
speciﬁcally with CDK4 and CDK6; while the CIP/KIP family,
including p21WAF1/CIP1, p27KIP1, and p57KIP2, inhibit a
broader spectrum of CDKs [9]. In particular, p21 and p27 bind
to all the G1 and G1 to S CDK complexes, but preferentially
inhibit the ones containing CDK2, via p53-dependent or p53-
independent mechanisms [8,10,11].
In addition to CDK inhibitors, the protein product of the
retinoblastoma tumor-suppressor gene (pRB), a member of the
pocket protein family, also serves as a negative regulator of cell
proliferation through its regulation of the E2F transcription
factors [12,13]. The cyclin-CDK complexes phosphorylate pRB
and related family proteins, thereby preventing their growth-
repressive functions. The phosphorylation of pRB in mid-G1
negates the ability of pRB to repress transcription, thereby
resulting in increased expression of cyclin E, the regulatory
partner for CDK2 [12,14]. The resulting cyclin E/CDK2
complexes phosphorylate pRB, causing the release of free
E2Fs and the activation of transcription of several genes
involved in the regulation of S phase [13,15]. Therefore,
strategies that could halt cell cycle progression by targeting
CDK inhibitors or pRB-related proteins could be useful as po-
tential molecular targets of cancer therapy [16–18].
For thousands of years, herbal medicines have been used in
many countries, with apparent safety and efﬁcacy, to alleviate and
treat various diseases, including cancer [19]. Interest is nowgrowing
in the pharmacological activity of traditional herbs that are widely
used in traditional medicine, and numerous studies support the
potential clinical beneﬁt of these medicines for treatment of
diseases recalcitrant diseases, like cancer [20,21]. Among these are
medicines derived from Kalopanax septemlobus (Thunb.) Koidz.
(common name: prickly castor oil tree) (K. septemlobus), a
deciduous tree in the family Araliaceae. This tree, native to
northeastern Asia, has long been valued for its
ethnopharmacology, being used for the treatment of rheumatic
arthritis, nephritis edema, cholera, dysentery, and neurotic pain.
Recent evidence shows that the extracts and/or components of
K. septemlobus show diverse pharmacological activities,
including anti-oxidant, anti-inﬂammatory, hypoglycemic, and
neurite outgrowth functions [22–25]. However, the actual mode of
the anti-cancer effects and the underlying cellular mechanisms
remain to be established. In this study, as a part of our search for
novel biologically active substances from traditional medicinal
resources for the prevention and treatment of cancers, we investi-
gated the potential of an ethanol extract of K. septemlobus leaves
(EEKS) to modulate the growth and proliferation of human HCC
cells. We demonstrated that EEKS treatment results in growth ar-
rest at the G1 to S transition of the cell cycle in HepG2 cells. We
further investigated the molecular mechanisms associated with theeffects ofEEKSbyanalyzing the inﬂuence ofEEKSon the proteins
involved in the G1 to S transition.2. Materials and methods
2.1. Preparation of EEKS
The leaves of K. septemlobus were obtained from Gurye Wild
Flower Institute (Gurye, Republic of Korea) and authenticated by
Professor S.H. Hong, Department of Biochemistry, Dongeui
University College of Korean Medicine (Busan, Republic of
Korea). The dried leaves (50 ı`g) were cut into small pieces, ground
into a ﬁne powder, and then soaked with 500 mL 70% ethanol
(500 mL) for 2 d. The extracted liquid was ﬁltered twice through
Whatman No. 3 ﬁlter paper to remove any insoluble materials and
was then concentrated using a rotary evaporator (EYELAN1000;
Rikakikai Co., Ltd., Tokyo, Japan). The extract (EEKS) was
dissolved in dimethylsulfoxide (DMSO; Sigma–Aldrich Co., St.
Louis, MO, USA) to a ﬁnal concentration of 200 mg/mL (extract
stock solution) and was subsequently diluted with medium to the
desired concentration prior to use.2.2. Cell culture
HCC HepG2 and Hep3B cell lines were purchased from
American Type Culture Collection (Manassas, VA, USA). The
cells were cultured at 37 C in humidiﬁed air with 5% CO2 in
RPMI-1640 medium (GIBCO-BRL, Gaithersburg, MD, USA),
supplemented with 10% fetal bovine serum (FBS), 100 units/mL
of penicillin, and 100 mg/mL of streptomycin, with or without
added EEKS.2.3. Cell proliferation assay
Cells were grown in 6-well multi-well plates (2 × 104 cells/
well) in media supplemented with EEKS at the indicated con-
centrations. After 24 h treatment, the cells were trypsinized and
viable cells were counted under an inverted microscope by
measuring the total cell number using the trypan blue dye
exclusion assay (Carl Zeiss, Jena, Germany). Data were reported
as the number of cells per well.
2.4. Cell cycle analysis by ﬂow cytometry
After treatment with various concentrations of EEKS for
24 h, the cells were harvested with trypsin, washed once with
phosphate-buffered saline, and ﬁxed in 70% ethanol overnight at
4 C. The cells were treated with 1 mg/mL RNase for 30 min at
37 C, and then stained with 10 ı`g/mL propidium iodide (PI,
Sigma–Aldrich Co.) for 30 min. Cells (10 000 per sample) were
analyzed using a ﬂow cytometer (Becton Dickinson, San Jose,
CA, USA). The distribution of DNA in the cell cycle was
determined using Modﬁt LT software (Verity Software House,
Topsham, ME, USA).
2.5. RNA isolation and reverse transcriptase polymerase
chain reaction (RT-PCR) analysis
Total RNA from the cultured cells was isolated using TRIzol
reagent (Invitrogen Life Technologies, Carlsbad, CA, USA)
Cheol Park et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(4): 344–350346according to the manufacturer's instructions. cDNA was synthe-
sized from 1 ı`g of total RNA, using AccuPower® RT PreMix
(Bioneer, Daejeon, Republic of Korea) containing Moloney mu-
rine leukemia virus reverse transcriptase. RT-generated cDNAs
were ampliﬁed by PCR using selective primers (Table 1), which
were purchased from Bioneer. After ampliﬁcation, the PCR re-
actions were electrophoresed in 1% agarose gels and visualized
with ethidium bromide (EtBr, Sigma–Aldrich Co.) staining. In a
parallel experiment, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as an internal control.
2.6. Total protein extraction, immunoprecipitation, and
Western blot analysis
After treatmentwith different concentrations of EEKS, the cells
were lysed in buffer containing 40 mM Tris (pH 8.0), 120 mM
NaCl, 0.5%Nonidet P-40, 0.1mMsodiumorthovanadate, 2 ı`g/mL
aprotinin, 2 ı`g/mL leupeptin, and 100 ı`g/mL phenymethylsulfonyl
ﬂuoride (Sigma–Aldrich Co.). Supernatants were collected and
protein concentrations were determined using the Bio-Rad protein
assay (Bio-Rad, Hercules, CA, USA). For immunoprecipitation,
cell extracts (500 ı`g) were incubated with immunoprecipitating
antibodies in extraction buffer for 2 h at 4 C, and then the
immunocomplexes were precipitated with protein A-Sepharose
beads (Sigma–Aldrich Co.). For Western blot assays, equalTable 1
Gene-speciﬁc primers for RT-PCR.
Gene name Primer sequences
Cyclin D1 Sense
Antisense
50-TGG ATG CTG GAG GTC TGC
GAG GAA-30
50-GGC TTC GAT CTG CTC CTG
GCA GGC-30
Cyclin E Sense
Antisense
50-AGT TCT CGG CTC GCT CCA
GGA AGA-30
50-TCT TGT GTC GCC ATA TAC
CGG TCA-30
CDK2 Sense
Antisense
50-GCT TTC TGC CAT TCT CAT
CG-30
50-GTC CCC AGA GTC CGA AAG
AT-30
CDK4 Sense
Antisense
50-ACG GGT GTA AGT GCC ATC
TG-30
50-TGG TGT CGG TGC CTA TGG
GA-30
CDK6 Sense
Antisense
50-CGA ATG CGT GGC GGA GAT
C-30
50-CCA CTG AGG TTA GAG CCA
TC-30
p53 Sense
Antisense
50-GCT CTG ACT GTA CCA CCA
TCC-30
50-CTC TCG GAA CAT CTC GAA
GCG-30
p21 Sense
Antisense
50-CTC AGA GGA GGC GCC
ATG-30
50-GGG CGG ATT AGG GCT TCC-
30
p27 Sense
Antisense
50-AAG CAC TGC CGG GAT ATG
GA-30
50-AAC CCA GCC TGA TTG TCT
GAC-30
GAPDH Sense
Antisense
50-CGG AGT CAA CGG ATT TGG
TCG TAT-30
50-AGC CTT CTC CAT GGT GGT
GAA GAC-30amounts of protein (30–50 ı`g/lane) and immunoprecipitated pro-
teins were subjected to electrophoresis on 8%–12% sodium
dodecyl sulfate (SDS)-polyacrylamide gels, and then transferred
onto nitrocellulose membranes (Schleicher and Schuell, Keene,
NH,USA).Themembraneswere blockedwithTris-buffered saline
(10mMTris-Cl, pH7.4) containing 0.5%Tween 20 and 5%nonfat
dry milk for 1 h at room temperature and then incubated with the
desired primary antibodies overnight. Membranes were then
washed with phosphate-buffered saline and incubated with the
secondary antibody conjugated to horseradish peroxidase (Amer-
sham Corp., Arlington Heights, IL, USA) for 1 h at room tem-
perature. Immunoreactivity was detected by using the enhanced
chemiluminescence (ECL) Western blotting detection system
(Amersham Corp.) according to the manufacturer's instructions.
Primary antibodies were purchased from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA,USA) andAbcam (Cambridge, UK).2.7. Cyclin D1-and E-associated kinase activity assay
Cell lysates from untreated and EEKS-treated cells were
incubated for 1 h at 4 C with anti-cyclin D1 and anti-cyclin E
antibodies. Immune-complexes were collected on protein A-
Sepharose beads (Sigma–Aldrich Co.) and resuspended in a
kinase assay mixture containing [€e-32P]ATP (ICN Biochemicals,
Irvine, CA, USA) and histone H1 (Sigma–Aldrich Co.) as
substrate. After incubation at 37 C for 30 min, the reaction was
stopped by the addition of the same amount of 2 × SDS sample
buffer. After boiling and spinning, the samples were separated
on 10% SDS-polyacrylamide gels and dried, and the bands were
detected by autoradiography.
2.8. Statistical analysis of data
The experiments were repeated three times, and the results
are expressed as means ± standard deviation (SD). A one-way
analysis of variance (ANOVA), followed by Dunnett's t-test,
was applied to assess the statistical signiﬁcance of the difference
among the study groups. A value of P < 0.05 was considered to
be statistically signiﬁcant.
3. Results
3.1. EEKS treatment suppresses cell proliferation of
HCC cells
The effect of EEKS treatment on HCC (HepG2 and Hep3B)
proliferation was determined by measuring the cell numbers
after treatment with EEKS for 24 h. As shown in Figure 1,
EEKS caused signiﬁcant concentration-dependent decreases in
cell numbers in both HepG2 and Hep3B cell lines; however, cell
proliferation was more signiﬁcantly suppressed by EEKS in
HepG2 cells than in Hep3B cells. Therefore, the HepG2 cell line
was selected for subsequent experiments.
3.2. EEKS treatment arrests cell cycle at G1 phase in
HepG2 cells
The possible mechanisms involved in the inhibition of cell
growth observed with EEKS treatment were analyzed by
ﬂuorescence-activated cell sorting to determine the distribution
of cells in various stages of the cell cycle. The percentages of G1
Figure 1. Inhibition of cell proliferation by treatment of human HCC cells
with EEKS.
*P < 0.05 vs. untreated control.
Figure 3. EEKS treatment induces hyperphosphorylation of pRB and en-
hances association of pRB and E2Fs in HepG2 cells.
(A) Cells were with the indicated concentrations of EEKS for 24 h, then
total cell lysates were prepared and separated by electrophoresis on 8% or
10% SDS-polyacrylamide gels. Western blotting was then performed using
anti-pRB, anti-E2F-1, and anti-E2F-4 antibodies. Actin was used as an
internal control. (B and C) Cells were incubated without or with EEKS (0.5
ı`g/mL) for 24 h, and then equal amounts of proteins were immunoprecip-
itated with the anti-E2F-1 (B) or anti-E2F-4 (C) antibody. Immuno-
complexes were separated by 8% SDS-polyacrylamide gel electropho-
resis, transferred to a nitrocellulose membrane, and probed with the anti-
pRB, E2F-1, and E2F-4 antibodies, respectively. Proteins were detected
by ECL detection (IP; immunoprecipitation).
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concentration-dependent manner (Figure 2). This G1 arrest was
accompanied by a reciprocal decrease in the percentage of cells
observed in the S phase; however, the percentage of cells in the
G2/M phase was not altered.
3.3. EEKS treatment downregulates pRB
phosphorylation and increases binding of pRB with
E2Fs in HepG2 cells
The pRB/E2F pathway constitutes the basic machinery
controlling the G1 to S transition and S phase entry [12,14];
therefore, we examined the effects of EEKS on the kinetics of
phosphorylation of pRB and the E2F transcription factors. The
immunoblotting data indicated that treatment of HepG2 cells
with EEKS for 24 h led to a concentration-dependent decreaseFigure 2. EEKS treatment induces G1 phase cell cycle arrest in HepG2 cells.
DNA content is represented on the x-axis and the number of cells counted is represented on the y-axis. Each point represents the mean of two independent
experiments.
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transcription factors such as E2F-1 and E2F-4 (ﬁgure 3A). We
assessed whether EEKS treatment increases the pRB/E2Fs
interaction by immunoprecipitation of cell extracts with E2F-1
and E2F-4 antibodies and probing with pRB antibodies, which
revealed an increase in the pRB levels in the E2F immunopre-
cipitates (Figure 3B and C).3.4. Effects of EEKS treatment on the levels of G1 phase-
associated cyclins and CDKs in HepG2 cells
The G1 phase CDKs (CDK2, CDK4 and CDK6) activities are
positively regulated by the bound cyclins such as D-type cyclins
(cyclin D1, D2 and D3) and cyclin E, but negatively by the CDK
inhibitors such as p21 and p27 [8,10,11]. We investigated whether
these molecular events were causally related to the EEKS-
induced G1 arrest by examining the response of HepG2 cells
to EEKS using RT-PCR and Western blot analyses. As shown in
Figure 4, the levels of CDK4 mRNA and protein were signiﬁ-
cantly decreased after treatment with EEKS at both the tran-
scriptional and translational levels, whereas the expression levelsFigure 4. Effects of EEKS treatment on the levels of G1-associated cyclins
and CDKs in HepG2 cells.
(A) Cells were treated with various concentrations of EEKS for 24 h, and
then total RNA was isolated and reverse-transcribed. The resulting cDNAs
were subjected to PCR with the indicated primers, and the reaction products
were separated on 1% agarose gel and visualized by EtBr staining. (B) The
cell lysates were prepared, and equal amounts of total cell lysates were
subjected to 10% SDS-polyacrylamide gel electrophoresis, transferred, and
probed with the indicated antibodies. GAPDH and actin were used as in-
ternal controls for the RT-PCR and Western blot assays, respectively.of other molecules, including CDK2, CDK6, cyclin D1, and
cyclin E, remained unchanged.
3.5. EEKS treatment increases the levels of p21 and p27
expression, inhibits G1 cyclin-associated kinase
activities in HepG2 cells
We examined the effects of EEKS on the expression of CDK
inhibitors p21 and p27 at the mRNA and protein levels. As
shown in Figure 5, EEKS caused a marked increase in expres-
sion of mRNA and protein of both of p21 and p27, whereas the
levels of tumor suppressor p53 were not altered following the
same treatment. Therefore, we evaluated the potential associa-
tion between the p21 and p27 proteins induced by EEKS
treatment and the CDKs, in order to further deﬁne the mecha-
nism of the G1 arrest response to EEKS. Co-
immunoprecipitation analyses revealed no detectable com-
plexes between p21 and CDK4/6 or between p27 and CDK4/6
in lysates from untreated control cells; however, treatment of
cells with EEKS resulted in a marked increase in the binding of
p21 and p27 with CDK4 and CDK6 (Figure 6A). We further
investigated the nature of G1 arrest following EEKS treatment
by evaluating the possible effects of EEKS on the modulation of
G1 cyclin-associated kinase activities using histone H1 as the
substrate. As shown in Figure 6B, treatment of HepG2 cells with
EEKS reduced the cyclin D1-and E-associated kinase activity in
a concentration-dependent manner.Figure 5. EEKS treatment induced p21 and p27 expression in HepG2
cells.
(A) Cells were treated with various concentrations of EEKS for 24 h, and
then total RNA was isolated and reverse-transcribed. The resulting cDNAs
were then subjected to PCR with the indicated primers, and the reaction
products were separated on 1% agarose gel and visualized by EtBr staining.
(B) The cell lysates were prepared, and equal amounts of total cell lysates
were subjected to SDS-polyacrylamide gel electrophoresis, transferred, and
probed with the indicated antibodies. GAPDH and actin were used as in-
ternal controls for the RT-PCR and Western blot assays, respectively.
Figure 6. EEKS treatment induced association of p21 and p27 with CDKs,
and inhibited cyclin D1-and cyclin E-associated kinase activities in HepG2
cells.
(A) Cells were treated with EEKS (0.5 mg/ml) for 24 h, and then total cell
lysates were prepared and immunoprecipitated with the anti-CDK4 or anti-
CDK6 antibody. The immuno-complexes were separated on 12% SDS-
polyacrylamide gels, transferred onto nitrocellulose membranes, and pro-
bed with the indicated antibodies and an ECL detection system. (B) After
treatment with various concentrations of EEKS for 24 h, the cell lysates
were prepared and immunoprecipitated with the anti-cyclin D1 or anti-
cyclin E antibody, and kinase activity was assayed using histone H1 as
substrate.
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In the present study, we provide evidence that EEKS treat-
ment induces anti-proliferative activity through cell cycle arrest
in the G1 phase in human HCC cells, and particularly in the
HepG2 cell line. The observed increase in the G1 phase in
EEKS-treated HepG2 cells was accompanied by a reciprocal
decrease in the number of cells in the S phase, with no change in
the G2/M fraction.
The transition of the G1 to the S phase of the cell cycle
marks an irreversible commitment to DNA synthesis and pro-
liferation, and is strictly regulated by positive and negative
growth-regulatory signals [6,7]. The major cyclin-CDK com-
plexes involved in cell cycle progression from the G1 to the S
phase are cyclin D-CDK4/6 and cyclin E-CDK2, respectively
[26,27]. The protein products of the pRB family of tumor
suppressor proteins, such as pRB, p107 and p130 (referred to
as ‘pocket proteins,’ key regulators of G1 cell cycle
progression), are phosphorylated by a set of these cyclin-CDK
complexes [12,13]. Among the pRB family proteins, pRB is a
major negative regulator of cell division, and pRB
hyperphosphorylation is a hallmark of the G1 to S transition
in the cell cycle. The phosphorylation of pRB causes
breakdown of the pRB/E2Fs complex, leading to liberation of
the E2F transcription factors that activate a transcription
program required for DNA synthesis, S-phase progression,
and cell division [14,15]. In contrast, dephosphorylated pRB
binds to E2Fs, thereby blocking their inhibitory activity and
allowing the cell to progress to the S phase [6,7]. Therefore,
decreases in either the levels of protein or in the association
between the respective binding partners are expected to cause
a concomitant decrease in the degree of pRB phosphorylation.
In the present study, EEKS-treated HepG2 cells showed
decreased expression of phosphorylated pRB, along withincreased binding of pRB to E2Fs, such as E2F-1 and E2F-4.
The data indicate that EEKS represses the transcriptional ac-
tivity of E2Fs for S phase entry by promoting their binding with
pRB in HepG2 cells.
The cyclin-CDK complexes are also known to bind to CDK
inhibitors, thereby inhibiting their kinase activities and restraining
cells in a particular phase of the cell cycle [27,28]. Expression of G1
cyclins is reported inmany human cancers: theD-type cyclins bind
to CDK4 and CDK6 in early G1 and act as growth sensors,
providing a link between mitogenic stimuli and the cell cycle
[27,28]. On the other hand, cyclin E, which is expressed in late
G1, forms an active kinase complex with CDK2 and contributes
to the G1 to S transition in the cell cycle [6,29]. It was shown that
EEKS partially inhibited the expression of CDK4 mRNA and
protein; however, little change was detectable in the levels of
CDK2, CDK6, cyclin D1, and cyclin E.
The CIP/KIP family is involved in regulation of G1 and S
phase of the cell cycle [8,27]. Generally, p21 blocks cell
proliferation in response to DNA damage or replication stress
by the inactivation of CDK2 by either cyclin E in the G1
phase or by cyclin A in the S phase [8,30]. Likewise, p27 also
suppresses cyclin E-CDK2 as well as D-type cyclins-CDK4
complexes and helps the cells to withdraw from the cell cycle
when they terminally differentiate [10,31]. We observed a
signiﬁcant induction of p21 and p27 at both the transcriptional
and translational levels in response to EEKS treatment,
whereas the expression of p53 was unchanged. Interestingly,
this was accompanied by an enhanced association of p21 and
p27 with CDK4 and CDK6, as indicated by co-
immunoprecipitation analysis. In addition, the results from the
immuno-complex kinase assays demonstrated that EEKS
downregulated both cyclin D1-and cyclin E-associated kinase
activities. These data suggest that the capability of EEKS to
arrest HepG2 cells in the G1 phase might be linked to the in-
hibition of CDK kinase activity through binding of the CDK
inhibitor proteins p21 and p27 to the cyclin-CDK complexes.
Taken together, our data suggested that EEKS induced G1
arrest in association with an inhibition of G1 cyclin-CDK
complex activity, rather than by altering the levels of G1
cyclins and CDK proteins. The result was an accumulation of
hypo-phosphorylated, growth-inhibitory pRB that suppressed
the E2F pathway in HepG2 cells. Further investigation is needed
to identify the biologically active compounds of EEKS respon-
sible for the observed effects; nevertheless, EEKS may have
signiﬁcant potential for development as a cancer treatment.
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